Unequal Behaviour between Hydrolysable Functions of Nirmatrelvir under Stress Conditions: Structural and Theoretical Approaches in Support of Preformulation Studies

• Egile Nagusiak: Philippe-Henri Secretan (Egilea), Maxime Annereau (Egilea), Willy Kini-Matondo (Egilea), Bastien Prost (Egilea), Jade Prudhomme (Egilea), Lina Bournane (Egilea), Muriel Paul (Egilea), Najet Yagoubi (Egilea), Hassane Sadou-Yayé (Egilea), Bernard Do (Egilea)
• Formatua: Liburua
• Argitaratua: MDPI AG, 2022-08-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Nirmatrelvir is an antiviral drug approved for the treatment of COVID-19. The available dosage form consists of tablets marketed under the brand name PAXLOVID^®. Although knowledge of nirmatrelvir's intrinsic stability may be useful for any potential development of other p...